PTC Therapeutics Investor Relations Material
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. The company's commercial product is Emflaza (deflazacort) used for the treatment of Duchenne muscular dystrophy in ambulatory patients aged 5 years and older. Its lead product candidate is Translarna that is completed Phase III clinical trials for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; which has completed Phase II/III clinical trials for the treatment of cystic fibrosis; and that is under preclinical development stage for the treatment of myotonic dystrophy type 1.
Edward "Ted" Decker's Rise to the Top at Home Depot
Explore Ted Decker's transformative impact on Home Depot, including his leadership in retail innovation and strategic vision alongside Craig Menear.
15 Feb 2024
Andy Jassy: Amazon CEO & Pioneer of Cloud Computing
Discover Andy Jassy's remarkable achievements at Amazon, including the creation of Amazon Web Services and his experiences working with Jeff Bezos.
15 Feb 2024
Stripe’s Rumored 2024 IPO
Anticipation grows around Stripe's rumored 2024 IPO, spotlighting its significant influence in the digital payments sector.
9 Feb 2024
🇺🇸 United States